Promising early Phase 1 test results for Medicago’s COVID-19 vaccine
By CP STAFFIndustry Manufacturing biotechnology COVID Test vaccine
100% of subjects developed a promising antibody response after two doses.
QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.
The Quebec City-based biotechnology company says interim results of a Phase 1 clinical trial found that 100% of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.
Medicago says the side effects were generally mild to moderate and short in duration.
The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.
Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.
The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.